Intellipharmaceutics Announces Resignation of Chief Financial Officer

Author's Avatar
Feb 05, 2020
Article's Main Image

TORONTO, ON / ACCESSWIRE / February 5, 2020 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced the resignation of Greg Powell, Chief Financial Officer, for personal and family reasons. Mr. Powell has agreed to continue to offer his services to the Company through March 4, 2020 and is willing to continue thereafter on a consulting basis on mutually agreeable terms.